Cerebral, a provider of digital mental health services, has acquired ADHD-focused app developer Inflow as part of its effort to broaden its treatment capabilities and enhance patient support beyond clinical interactions. Financial terms of the transaction were not disclosed.
Inflow’s platform is grounded in cognitive behavioural therapy (CBT) principles and delivers structured, skills-based modules designed to help users build awareness, modify behaviors, and manage ADHD symptoms in daily life. The app has demonstrated efficacy in prior research, with users reporting reductions in symptoms and functional impairment.
Cerebral indicated that integrating Inflow will enable the company to provide “continuous support options” for ADHD patients, complementing its existing services such as medication management and telehealth consultations. The addition is intended to strengthen patient engagement between appointments and support long-term condition management.
Dr Carl Marci, chief medical officer at Cerebral, emphasized the growing demand for scalable ADHD solutions, stating: “High-quality ADHD treatments are a significant and growing area of need, underscoring the importance of scalable, validated tools that offer support both during and in between sessions.”
The acquisition comes amid increasing activity in the digital ADHD treatment landscape. Several companies are advancing regulated digital therapeutics and software-based interventions aimed at improving attention and cognitive function.
Lumos Labs received US Food and Drug Administration (FDA) clearance in December 2025 for LumosityRx, a prescription digital therapeutic designed to improve attention span in adults with ADHD through cognitive training exercises used alongside medication and therapy.
Akili previously secured FDA clearance for EndeavorOTC, a mobile-based video game treatment. In the STARS-ADHD-Adult trial (NCT05183919), 72.5% of participants reported improvements in quality of life as measured by the Adult ADHD Quality of Life Scale.
Market forecasts indicate continued growth in ADHD diagnoses across major markets. According to GlobalData, diagnosed prevalent cases across the seven major markets are expected to increase from 21.1 million in 2022 to 22 million by 2032, driven in part by more standardized screening and diagnostic practices.
The integration of Inflow positions Cerebral to further develop a hybrid care model that combines clinician-led services with digital therapeutic tools, reflecting broader shifts toward continuous and personalized mental healthcare delivery.
Click here for the original news story.